Hind.Bio Science

{
  "main_header": {
    "sid": 395126,
    "name": "Hind.Bio Science",
    "stock_name": "Hind.Bio Science",
    "full_name": "Hindustan Bio Sciences Ltd",
    "name_url": "stocks-analysis/hindbio-science",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "7.47",
    "chg": 0.35,
    "chgp": "4.92%",
    "dir": 1,
    "prev_price": "7.12",
    "mcapval": "7.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 532041,
    "symbol": "",
    "ind_name": "Software Products",
    "ind_code": 4,
    "sector_id": 73,
    "indexname": "India SENSEX",
    "isin": "INE597C01021",
    "curr_date": "Jul 17, 03:30 PM",
    "curr_time": "03:03 AM",
    "last_traded_at": "Jul 17, 03:30 PM IST",
    "bse_nse_vol": "16.14 k",
    "exc_status": "Active",
    "traded_date": "Jul 17, 2026",
    "traded_date_str": "2026 07 17",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/hindbio-science-395126-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Are Hindustan Bio Sciences Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-hindustan-bio-sciences-ltd-latest-results-good-or-bad-4032376",
        "imagepath": "",
        "date": "2026-06-02 19:28:22",
        "description": "Hindustan Bio Sciences Ltd has reported concerning financial results for the quarter ended March 2026, reflecting significant operational challenges. The company recorded net sales of ₹0.00 crores, a complete decline from ₹0.38 crores in the previous quarter, indicating a 100% quarter-on-quarter drop. This pattern of alternating quarters with zero revenue raises serious concerns about the company's operational viability and market presence.\n\nIn terms of profitability, Hindustan Bio Sciences experienced a net loss of ₹0.12 crores in Q4 FY26, a stark contrast to the net profit of ₹0.08 crores reported in the prior quarter. The operating profit before depreciation, interest, and tax (PBDIT) also stood at negative ₹0.12 crores, highlighting the company's inability to cover basic operational expenses without revenue generation.\n\nThe company's return on equity (ROE) was reported at 8.60%, with the latest quarter ..."
      },
      {
        "title": "Hindustan Bio Sciences Q4 FY26: Revenue Collapse Signals Deepening Operational Crisis",
        "link": "https://www.marketsmojo.com/news/result-analysis/hindustan-bio-sciences-q4-fy26-revenue-collapse-signals-deepening-operational-crisis-4028761",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/HindustanBioSci_quaterlyResult_4028761.png",
        "date": "2026-06-01 15:05:42",
        "description": "Hindustan Bio Sciences Ltd. reported a complete revenue collapse in Q4 FY26, with net sales plummeting to zero from ₹0.38 crores in the previous quarter, whilst simultaneously posting a net loss of ₹0.12 crores. The micro-cap pharmaceutical company, valued at just ₹8.32 crores, saw its shares decline 4.47% to ₹8.12 following the dismal quarterly performance, extending its one-year loss to 17.23%."
      },
      {
        "title": "Are Hindustan Bio Sciences Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-hindustan-bio-sciences-ltd-latest-results-good-or-bad-4023816",
        "imagepath": "",
        "date": "2026-05-30 19:45:11",
        "description": "Hindustan Bio Sciences Ltd's latest financial results for Q3 FY26 indicate a complex operational landscape characterized by significant revenue volatility and structural challenges. The company reported net sales of ₹0.38 crores, a recovery from zero sales in the previous quarter, which underscores the erratic nature of its revenue generation. This pattern raises concerns about the sustainability of its business model, especially given the company's five-year sales growth rate of -16.00%.\n\nThe net profit for the quarter was ₹0.08 crores, marking a recovery from a loss of ₹0.06 crores in the prior quarter. This profit recovery, while positive, is set against a backdrop of historical inconsistency, as the average return on equity (ROE) over recent years stands at 0.0%. The latest quarter's ROE of 14.00% reflects better capital efficiency when the company is operational, but this is not indicative of a stable ..."
      },
      {
        "title": "When is the next results date for Hindustan Bio Sciences Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-hindustan-bio-sciences-ltd-4001676",
        "imagepath": "",
        "date": "2026-05-20 23:18:16",
        "description": "The next results date for Hindustan Bio Sciences Ltd is scheduled for 30 May 2026...."
      }
    ],
    "total": 106,
    "sid": "395126",
    "stock_news_url": "https://www.marketsmojo.com/news/hindustan-bio-sciences-395126"
  },
  "announcements": [
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "09-Jul-2026",
      "details": "We are hereby submitting the Compliance Certificate issued by Venture Capital and Corporate Investments Private Limited in compliance with 74(5) of SEBI(D&P) Regulations2018 for the first quarter ended 30th June 2026",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "27-Jun-2026",
      "details": "The trading window for dealing in the securities of the company will remain closed from 01st July 2026 till 48 hours after announcement of Standalone Un-Audited Financial results for the quarter ending on June 30 2026",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "02-Jun-2026",
      "details": "Newspaper publication as per regulation 47 of SEBI (LODR) 2015.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Are Hindustan Bio Sciences Ltd latest results good or bad?

2026-06-02 19:28:22

Hindustan Bio Sciences Ltd has reported concerning financial results for the quarter ended March 2026, reflecting significant operational challenges. The company recorded net sales of ₹0.00 crores, a complete decline from ₹0.38 crores in the previous quarter, indicating a 100% quarter-on-quarter drop. This pattern of alternating quarters with zero revenue raises serious concerns about the company's operational viability and market presence. In terms of profitability, Hindustan Bio Sciences experienced a net loss of ₹0.12 crores in Q4 FY26, a stark contrast to the net profit of ₹0.08 crores reported in the prior quarter. The operating profit before depreciation, interest, and tax (PBDIT) also stood at negative ₹0.12 crores, highlighting the company's inability to cover basic operational expenses without revenue generation. The company's return on equity (ROE) was reported at 8.60%, with the latest quarter ...

Read full news article

Hindustan Bio Sciences Q4 FY26: Revenue Collapse Signals Deepening Operational Crisis

2026-06-01 15:05:42

Hindustan Bio Sciences Ltd. reported a complete revenue collapse in Q4 FY26, with net sales plummeting to zero from ₹0.38 crores in the previous quarter, whilst simultaneously posting a net loss of ₹0.12 crores. The micro-cap pharmaceutical company, valued at just ₹8.32 crores, saw its shares decline 4.47% to ₹8.12 following the dismal quarterly performance, extending its one-year loss to 17.23%.

Read full news article

Are Hindustan Bio Sciences Ltd latest results good or bad?

2026-05-30 19:45:11

Hindustan Bio Sciences Ltd's latest financial results for Q3 FY26 indicate a complex operational landscape characterized by significant revenue volatility and structural challenges. The company reported net sales of ₹0.38 crores, a recovery from zero sales in the previous quarter, which underscores the erratic nature of its revenue generation. This pattern raises concerns about the sustainability of its business model, especially given the company's five-year sales growth rate of -16.00%. The net profit for the quarter was ₹0.08 crores, marking a recovery from a loss of ₹0.06 crores in the prior quarter. This profit recovery, while positive, is set against a backdrop of historical inconsistency, as the average return on equity (ROE) over recent years stands at 0.0%. The latest quarter's ROE of 14.00% reflects better capital efficiency when the company is operational, but this is not indicative of a stable ...

Read full news article

When is the next results date for Hindustan Bio Sciences Ltd?

2026-05-20 23:18:16

The next results date for Hindustan Bio Sciences Ltd is scheduled for 30 May 2026....

Read full news article

View All News